Bernard Lichtenstein, MD
Internal Medicine · San Diego, CANPI 1104878073
Payments from drug & device makers
Across 65 payments — averaging $37.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$854
- AbbVie$398
- Novo Nordisk$391
- Amgen$251
- AstraZeneca$205
- Melinta Therapeutics, LLC$119
- plus $223 from 9 others
What the payments were for
- Food & beverage$2,442100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $854 |
| AbbVie(2 entities) | 13 | $398 |
| Novo Nordisk | 9 | $391 |
| Amgen | 3 | $251 |
| AstraZeneca | 7 | $205 |
| Melinta Therapeutics, LLC | 5 | $119 |
| Vision Quest Industries Inc. | 3 | $60 |
| GSK | 2 | $44 |
| Genentech USA, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,442 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $241,604 |
| FarxigaDapagliflozin Propanediol | 78 | $57,974 |
| Invega SustennaPaliperidone Palmitate | 23 | $51,782 |
| TrulicityDulaglutide | 36 | $37,899 |
| EliquisApixaban | 51 | $31,997 |
| LinzessLinaclotide | 41 | $22,729 |
| TradjentaLinagliptin | 27 | $18,268 |
| RexultiBrexpiprazole | 12 | $18,254 |
| JardianceEmpagliflozin | 23 | $17,549 |
| XareltoRivaroxaban | 28 | $17,208 |
| RybelsusSemaglutide | 17 | $15,427 |
| Spiriva HandihalerTiotropium Bromide | 16 | $12,033 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,135 |
| EntrestoSacubitril/Valsartan | 11 | $10,819 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $8,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $391 | $257,031262 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $854 | $68,99051 claims |
| AstraZenecaFarxiga | $205 | $57,97478 claims |
| Lilly USA, LLCTrulicity | $14 | $37,89936 claims |
| AbbVieLinzess | $398 | $22,72941 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $44 | $16,14829 claims |
| NovartisEntresto | $19 | $10,81911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Diego
- Donald BrandonSan Diego$34M
- Elaine WatkinsSan Diego$11.3M
- James ChenSan Diego$2.9M
- Rita StarrittSan Diego$2.6M
- Hatim HusainSan Diego$2.6M
- Gary FiresteinSan Diego$2.6M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.